Market Research Future (MRFR) has published a cooked research report on the “Global Pharmaceutical Digital Platform that contains the information from 2019 to 2032. The Global Pharmaceutical Digital Platform Market is estimated to register a CAGR of 24.35% during the forecast period of 2024 to 2032.
MRFR recognizes the following companies as the key players in the Global Pharmaceutical Digital Platform Industry - AstraZeneca (UK), Pfizer, Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Sanofi (France), Astellas Pharma Inc. (Japan), Boehringer Ingelheim International GmbH (Germany), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US).
Market Highlights
The Global Pharmaceutical Digital Platform Market is expected to register a CAGR of 24.35% during the forecast period and is estimated to reach USD 34.12 billion by 2032.
The Global Pharmaceutical Digital Platform Market is increasing adoption of digital health solutions and growing penetration of the internet, coupled with the growing digitization in healthcare infrastructure. Additionally, the rising awareness and education associated with the pharmaceutical digital platform will provide growth opportunities for the market in the future.
Segment Analysis
The Global Pharmaceutical Digital Platform Market has been segmented based on Services, Disease, and End Use.
Based on Services, the global Pharmaceutical Digital Platform market has been segmented into Tele Consultation, In-Person Care, Vaccine Scheduling, and Medicine Delivery. The Tele Consultation segment dominated the market in 2023, and Medicine Delivery is projected to be the fastest-growing segment during the forecast period, 2024–2032. For Instance, as of February 2023, more than 7.4 million teleconsultations had been conducted through the eSanjeevani portal in India, reflecting a steady rise since March 2022. These consultations took place at various Ayushman Bharat Health and Wellness Centers across the country. The eSanjeevani platform was launched by the Union Ministry of Health and Family Welfare as a national telemedicine service. eSanjeevani facilitates remote medical consultations, making healthcare more accessible, especially for individuals in rural and underserved areas. The platform operates through various Ayushman Bharat Health and Wellness Centers, providing a range of services from primary care to specialized consultations.
Browse In-depth Details [Table of Content, List of Figures, List of Tables] of Pharmaceutical Digital Platform Market Outlook
Based on Disease, the global Pharmaceutical Digital Platform market has been segmented into Migraine, Diabetes, Obesity, Pneumococcal pneumonia, Flu, and Others. The Diabetes segment dominated the market in 2023, and obesity is projected to be the fastest-growing segment during the forecast period, 2024–2032. For Instance, according to IDF Diabetes Atlas, in 2021, approximately 537 million adults aged 20 to 79 were living with diabetes, equating to 1 in 10 individuals. This figure is expected to rise to 643 million by 2030 and 783 million by 2045. Notably, more than three-quarters of adults with diabetes reside in low- and middle-income countries. The disease was responsible for 6.7 million deaths in 2021, translating to one death every five seconds. Additionally, diabetes incurred health expenditures of at least USD 966 billion, marking a staggering 316% increase over the past 15 years. Additionally, in 2022, 1 in 8 people globally were living with obesity. Since 1990, adult obesity has more than doubled, while adolescent obesity has quadrupled. That year, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Among adults, 43% were overweight and 16% were obese. Additionally, 37 million children under the age of 5 were identified as overweight, and over 390 million children and adolescents aged 5 to 19 were also overweight, including 160 million who were living with obesity.
Based on end use, the global Pharmaceutical Digital Platform market has been segmented into Disease Treatment, and Disease Prevention. The Disease Treatment segment dominated the market in 2023, and Disease Prevention is projected to be the fastest-growing segment during the forecast period, 2024–2032. Disease treatment involves a comprehensive approach to managing and alleviating the effects of illnesses, focusing on restoring health and enhancing the quality of life for patients. Disease treatment and disease prevention are closely interconnected, as effective treatment strategies can significantly impact prevention efforts. When diseases are treated promptly and appropriately, it can reduce the overall prevalence and severity of the disease in the population. In contrast, Disease Prevention is proactive, aiming to avert the onset of diseases before they occur. This can be achieved through primary prevention measures like vaccinations, health education, and lifestyle modifications that reduce risk factors. Secondary prevention involves early detection and prompt intervention to halt disease progression, while tertiary prevention focuses on managing existing conditions to prevent further deterioration.
Regional Analysis
Based on region, the Global Pharmaceutical Digital Platform Market has been segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the largest market share in 2023.
North America accounted for the largest market share and is estimated to dominate the global Pharmaceutical Digital Platform market. In 2021, crude estimates indicated that 38.4 million people of all ages, or 11.6% of the U.S. population, were living with diabetes. Additionally, heart disease remains the leading cause of death across men, women, and various racial and ethnic groups in the United States. On average, someone dies from cardiovascular disease every 33 seconds. In 2022, heart disease claimed the lives of 702,880 individuals, accounting for approximately 1 in every 5 deaths.
The Americas region is followed by Europe, which accounted for the second largest Pharmaceutical Digital Platform market share. In 2020, Germany led the EU Member States in current healthcare expenditure, amounting to €432 billion. France followed with €281 billion, while Italy and Spain recorded €160 billion and €120 billion, respectively. Current healthcare spending in Germany and France represented 12.8% and 12.2% of their gross domestic product (GDP), the highest percentages among EU countries. Austria (11.5%), Sweden (11.4%), the Netherlands (11.1%), and Belgium (11.1%) had the next highest ratios. Spain, Portugal, and Denmark were the only other EU Member States with double-digit ratios. Additionally, Switzerland had a current healthcare expenditure of 11.8% of GDP, and Norway also reported a double-digit ratio based on 2019 data. In contrast, six Member States spent less than 7.5% of GDP on healthcare, with Luxembourg having the lowest ratio.
Key Findings of the Study
- The Global Pharmaceutical Digital Platform Market is expected to reach USD 34.12 billion by 2032, at a CAGR of 24.35% during the forecast period.
- The Asia-Pacific region accounted for the fastest-growing global market.
- Based on Services, Tele-Consultation segment held the majority share in 2023.
- AstraZeneca (UK), Pfizer, Inc. (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bayer AG (Germany), Sanofi (France), Astellas Pharma Inc. (Japan), Boehringer Ingelheim International GmbH (Germany), Gilead Sciences, Inc. (US), Bristol-Myers Squibb Company (US). are the key market players.
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Base Year | 2023 |
Companies Covered | 15 |
Pages | 100 |
Certified Global Research Member
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.